Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.

ABSTRACT: Patients with hepatocellular carcinoma (HCC) accompanying portal vein tumor thrombosis (PVTT) have relatively few therapeutic options and an extremely poor prognosis. These patients are classified into barcelona clinic liver cancer stage C and sorafenib is suggested as the standard therapy of care. However, overall survival (OS) gain from sorafenib is unsatisfactory and better treatment modalities are urgently required. Therefore, we critically appraised recent data for the various treatment strategies for patients with HCC accompanying PVTT. In suitable patients, even surgical resection can be considered a potentially curative strategy. Transarterial chemoembolization (TACE) can be performed effectively and safely in a carefully chosen population of patients with reserved liver function a

SUBMITTER: Yu SJ 

PROVIDER: S-EPMC4462693 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature